180 related articles for article (PubMed ID: 30467723)
1. Early response evaluation of neoadjuvant therapy with PET/MRI to predict resectability in patients with adenocarcinoma of the esophagogastric junction.
Belmouhand M; Löfgren J; Johannesen HH; Baeksgaard L; Gutte H; Tariq K; Achiam MP
Abdom Radiol (NY); 2019 Mar; 44(3):836-844. PubMed ID: 30467723
[TBL] [Abstract][Full Text] [Related]
2. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
Lorenzen S; von Gall C; Stange A; Haag GM; Weitz J; Haberkorn U; Lordick F; Weichert W; Abel U; Debus J; Jäger D; Münter MW
BMC Cancer; 2011 Jun; 11():266. PubMed ID: 21702914
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Response to Neoadjuvant Chemoradiotherapy by 18F-FDG PET/CT in Patients With Locally Advanced Esophagogastric Junction Adenocarcinoma.
Sánchez-Izquierdo N; Perlaza P; Pagès M; Buxó E; Rios J; Rubello D; Colletti PM; Mayoral M; Casanueva S; Fernández-Esparrach G; Ginés A; Fuster D
Clin Nucl Med; 2020 Jan; 45(1):38-43. PubMed ID: 31714278
[TBL] [Abstract][Full Text] [Related]
4. Assessment of diffusion-weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction.
Weber MA; Bender K; von Gall CC; Stange A; Grünberg K; Ott K; Haberkorn U; Kauczor HU; Zechmann C
J Gastrointestin Liver Dis; 2013 Mar; 22(1):45-52. PubMed ID: 23539390
[TBL] [Abstract][Full Text] [Related]
5. Metabolic response evaluation by PET during neoadjuvant treatment for adenocarcinoma of the esophagus and esophagogastric junction.
Sendler A
Recent Results Cancer Res; 2010; 182():167-77. PubMed ID: 20676880
[TBL] [Abstract][Full Text] [Related]
6. The value of 18F-FDG-PET testing in the management of esophageal and gastroesophageal junction adenocarcinoma - review.
Zemanová M; Obermannová R; Haruštiak T
Klin Onkol; 2021; 34(2):113-119. PubMed ID: 33906359
[TBL] [Abstract][Full Text] [Related]
7. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
Lordick F; Ott K; Krause BJ; Weber WA; Becker K; Stein HJ; Lorenzen S; Schuster T; Wieder H; Herrmann K; Bredenkamp R; Höfler H; Fink U; Peschel C; Schwaiger M; Siewert JR
Lancet Oncol; 2007 Sep; 8(9):797-805. PubMed ID: 17693134
[TBL] [Abstract][Full Text] [Related]
8. Response to chemotherapy in gastric adenocarcinoma with diffusion-weighted MRI and (18) F-FDG-PET/CT: correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade.
Giganti F; De Cobelli F; Canevari C; Orsenigo E; Gallivanone F; Esposito A; Castiglioni I; Ambrosi A; Albarello L; Mazza E; Gianolli L; Staudacher C; Del Maschio A
J Magn Reson Imaging; 2014 Nov; 40(5):1147-57. PubMed ID: 24214734
[TBL] [Abstract][Full Text] [Related]
9. [
Harustiak T; Zemanova M; Fencl P; Hornofova L; Pazdro A; Snajdauf M; Salkova E; Lischke R; Stolz A
Br J Surg; 2018 Mar; 105(4):419-428. PubMed ID: 29417984
[TBL] [Abstract][Full Text] [Related]
10. Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography.
Lordick F
Recent Results Cancer Res; 2012; 196():201-11. PubMed ID: 23129376
[TBL] [Abstract][Full Text] [Related]
11. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
[TBL] [Abstract][Full Text] [Related]
12. PET-directed combined modality therapy for gastroesophageal junction cancer: Results of the multicentre prospective MEMORI trial of the German Cancer Consortium (DKTK).
Lorenzen S; Quante M; Rauscher I; Slotta-Huspenina J; Weichert W; Feith M; Friess H; Combs SE; Weber WA; Haller B; Angele M; Albertsmeier M; Blankenstein C; Kasper S; Schmid RM; Bassermann F; Schwaiger M; Liffers ST; Siveke JT
Eur J Cancer; 2022 Nov; 175():99-106. PubMed ID: 36099671
[TBL] [Abstract][Full Text] [Related]
13. Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival.
Panda A; Garg I; Truty MJ; Kline TL; Johnson MP; Ehman EC; Suman G; Anaam DA; Kemp BJ; Johnson GB; Halfdanarson TR; Venkatesh SK; Fidler JL; Goenka AH
AJR Am J Roentgenol; 2021 Sep; 217(3):730-740. PubMed ID: 33084382
[No Abstract] [Full Text] [Related]
14. Is there a role for PET/CT with esophagogastric junction adenocarcinoma?
Fuster D; Mayoral M; Rubello D; Pineda E; Fernández-Esparrach G; Pagès M; Colletti PM; Pons F
Clin Nucl Med; 2015 Mar; 40(3):e201-7. PubMed ID: 25546207
[TBL] [Abstract][Full Text] [Related]
15. Restaging of rectal cancer with hybrid positron emission tomography magnetic resonance imaging after preoperative chemoradiotherapy.
Tey J; Tan JK; Tan KK; Soon YY; Loi HY; Mohamed JSA; Bakulbhai PA; Ang B; Liang TY
Ann Acad Med Singap; 2023 Jun; 52(6):289-295. PubMed ID: 38904510
[TBL] [Abstract][Full Text] [Related]
16. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
[TBL] [Abstract][Full Text] [Related]
17. Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma.
Ku GY; Kriplani A; Janjigian YY; Kelsen DP; Rusch VW; Bains M; Chou J; Capanu M; Wu AJ; Goodman KA; Ilson DH
Cancer; 2016 Jul; 122(13):2083-90. PubMed ID: 27152857
[TBL] [Abstract][Full Text] [Related]
18. Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography.
Roedl JB; Harisinghani MG; Colen RR; Fischman AJ; Blake MA; Mathisen DJ; Mueller PR
Ann Thorac Surg; 2008 Oct; 86(4):1131-8. PubMed ID: 18805147
[TBL] [Abstract][Full Text] [Related]
19. Association of dynamic contrast-enhanced MRI and
Withey SJ; Owczarczyk K; Grzeda MT; Yip C; Deere H; Green M; Maisey N; Davies AR; Cook GJ; Goh V;
Eur J Surg Oncol; 2023 Oct; 49(10):106934. PubMed ID: 37183047
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response.
Gerbaudo VH; Killoran JH; Kim CK; Hornick JL; Nowak JA; Enzinger PC; Mamon HJ
Ann Nucl Med; 2018 Apr; 32(3):165-174. PubMed ID: 29332233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
